Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer as Part of an Early Access Program

NCT07563205 is registered in ClinicalTrials.gov with GFPC Investigation as lead sponsor.

NCT NCT07563205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07563205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer as Part of an Early Access Program
Lead sponsor
GFPC Investigation
Phase
Observational
Overall status
Recruiting
Start date
November 19, 2025
Completion date
November 19, 2027
Enrollment
100 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

egfr, egfr exon 19 deletion mutation, egfr exon 20 insertion mutation, egfr exon 21 mutation, non small cell lung cancer metastatic, non small cell lung cancer nsclc, non small cell lung carcinoma, non-small cell lung cancer, nsclc